Navigation Links
Data Show ARIMIDEX(R) (Anastrozole) Continues To Be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
Date:12/14/2007

Effectiveness Of ARIMIDEX Still Evident More Than Three Years After

Treatment

SAN ANTONIO, Texas, Dec. 14 /PRNewswire-FirstCall/ -- Data released today show a continued benefit of ARIMIDEX when compared to tamoxifen in treating postmenopausal women with hormone receptor-positive (HR+) early breast cancer. Results of the ATAC (ARIMIDEX, Tamoxifen, Alone or in Combination) trial, reported today at the 2007 San Antonio Breast Cancer Symposium, represent a median follow-up of more than eight years and show an absolute reduction in the risk of recurrence and distant recurrence with ARIMIDEX. The ATAC trial is one of the world's longest and largest breast cancer studies and is supported by AstraZeneca.

With approximately 2.5 million breast cancer survivors in the United States today, the ATAC 100-month analysis marks a major milestone in understanding the treatment of HR+ early breast cancer(1). The data show that the effects of ARIMIDEX in decreasing the risk of recurrence compared with tamoxifen continue even after patients have completed therapy.

At a median follow-up of 100 months, more than three years after the completion of treatment, ARIMIDEX significantly reduces the risk of recurrence in comparison with tamoxifen in postmenopausal patients with HR+ breast cancer. A significant benefit of ARIMIDEX on distant recurrence is now evident (HR+population p=0.027), and ARIMIDEX is also shown to reduce the risk of distant metastases. Although there was no difference in overall survival, the impact of ARIMIDEX at reducing distant metastases is important, as distant recurrence-free survival is an important predictor for survival related to breast cancer(2).

"The long-term data from the ATAC trial continue to impact the way physicians worldwide treat postmenopausal women with hormone receptor-positive early breast cancer," said Aman U. Buzdar, MD, who represents North America on the ATAC Steering Committe
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
2. Battle Continues Over Vietnam PTSD Numbers
3. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
4. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
5. Securians Minnesota Life Continues to Climb Group Life Rankings
6. USA TODAY Continues Spirit of the USA Charity Program as Part of Newspapers 25th Anniversary Celebration
7. United States continues to have highest level of health spending
8. LehmanMillet Continues Expansion with Strategic Hires
9. American Cancer Society report finds breast cancer death rate continues to drop
10. CIGNA HealthCare Continues Gains in Health Care Quality
11. Los Angeles Jewish Home Support Group Continues High-Profile Speaker Program With Noted Legal Scholar and Expert Laurie L. Levenson
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... New York (PRWEB) July 13, 2014 ... bring attention to the cancer risks associated with power ... to tell their story to federal regulators, as they ... U.S. Food & Drug Administration (FDA) advisory panel ... reports. According to the Rochester Democrat and Chronicle, ...
(Date:7/13/2014)... July 13, 2014 Recently, 2014QuinceaneraDresses.com, ... has unveiled its new range of gorgeous ... market, the demand for elegant Quinceanera outfits is ... beautiful items. All the company’s newly released dresses ... They are all elegant and vivid. , ...
(Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
(Date:7/13/2014)... California (PRWEB) July 13, 2014 Celebrity ... Musico has formed a promotional partnership with Aqua Health ... based Omega-3 EPA supplement . The collaboration was ... a celebrity fitness trainer , actor, model, and ... go-to trainer for A-List celebrities, he has prepared stars ...
(Date:7/13/2014)... July 13, 2014 According to the ... this is a comprehensive guide that features a series ... with KP (keratosis pilaris). This guide consists of ... Is Keratosis Pilaris? ,     Chapter 2: What Cause ... If I Have KP? ,     Chapter 4: Keratosis ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3
... WASHINGTON, March 28 Thousands of epilepsy advocates, caregivers, ... celebrities at the nation,s Capitol today to support the ... two years, the event has raised more than $2 ... event is expected to increase those numbers significantly. Money ...
... could replace anti-clotting drug warfarin for many patients, researchers ... implanted device may soon replace the anti-clotting drug warfarin ... with atrial fibrillation, a new study suggests. , People ... stroke, the researchers noted, and typically need to take ...
... in era of rising costs , , FRIDAY, March 27 (HealthDay ... national health care reform when she was first lady in ... are working -- are without health insurance. , That finding ... a state-by-state picture of people foregoing insurance because of rising ...
... Drug-eluting stents were safe and superior to bare metal ... "real-world" patients enrolled in a nationwide registry of cardiovascular ... , The findings were presented today at the ... Scientific Session. They also appear online in the ...
... (NYSE: NUS ) announced that more than 100,000 ... the company,s distributors and customers who have purchased Epoch Baobab ... company has donated $0.25 from the sale of every Epoch ... Foundation,s Seeds of Hope reforestation project. "When someone purchases a ...
... Earnings Guidance to a Minimum of $0.25 per diluted ... Service Corporation (Nasdaq: PRSC ) today announced ... December 31, 2008. Included in the results is ... related to the Company,s intangible assets, which, when added ...
Cached Medicine News:Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 2Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 3Health News:New Device Treats Common Heart Rhythm Disorder 2Health News:New Device Treats Common Heart Rhythm Disorder 3Health News:One in Five Working Adults Said to Lack Health Insurance 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 3Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 4Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 5Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 6Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 7Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 8Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 9Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 10Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 11Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 12Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 13Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 14
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Alacrita Set to Change the Face of Life Science Consulting -- LONDON, November 15, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
... announces that a new market research report is available ... Industry http://www.reportlinker.com/p080450/Global-Nuclear-Medicine-Industry.html ... in US$ Million by the following Product Segments: Gamma ... analytics for the US, Canada, Japan, Europe, Asia-Pacific, and ...
Cached Medicine Technology:Alacrita Set to Change the Face of Life Science Consulting 2Alacrita Set to Change the Face of Life Science Consulting 3Alacrita Set to Change the Face of Life Science Consulting 4Alacrita Set to Change the Face of Life Science Consulting 5Alacrita Set to Change the Face of Life Science Consulting 6Alacrita Set to Change the Face of Life Science Consulting 7Alacrita Set to Change the Face of Life Science Consulting 8Alacrita Set to Change the Face of Life Science Consulting 9Reportlinker Adds Global Nuclear Medicine Industry 2Reportlinker Adds Global Nuclear Medicine Industry 3Reportlinker Adds Global Nuclear Medicine Industry 4Reportlinker Adds Global Nuclear Medicine Industry 5Reportlinker Adds Global Nuclear Medicine Industry 6Reportlinker Adds Global Nuclear Medicine Industry 7Reportlinker Adds Global Nuclear Medicine Industry 8Reportlinker Adds Global Nuclear Medicine Industry 9Reportlinker Adds Global Nuclear Medicine Industry 10Reportlinker Adds Global Nuclear Medicine Industry 11Reportlinker Adds Global Nuclear Medicine Industry 12Reportlinker Adds Global Nuclear Medicine Industry 13Reportlinker Adds Global Nuclear Medicine Industry 14Reportlinker Adds Global Nuclear Medicine Industry 15Reportlinker Adds Global Nuclear Medicine Industry 16Reportlinker Adds Global Nuclear Medicine Industry 17Reportlinker Adds Global Nuclear Medicine Industry 18Reportlinker Adds Global Nuclear Medicine Industry 19
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
... EP Systems sells the popular transeptal ... needles. These products allow left atrial ... catheter ablation of left-sided arrhythmogenic substrates. ... others use it when a transaortic ...
Medicine Products: